TEL AVIV (MarketWatch) -- Novartis /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 54.82, -0.04, -0.07%) /quotes/comstock/06p!novn (CH:NOVN 57.80, -0.10, -0.17%) , the Basel health-care giant, received from the European Commission clearance to market Menveo ...
[Published Mar 18 2010 by MarketWatch]